Expertise in
4
conditions

Dr. Naoko Takebe

Hematology
OU Health Stephenson Cancer Center
800 NE 10th St, 
Oklahoma City, OK 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
OU Health Stephenson Cancer Center
800 NE 10th St, 
Oklahoma City, OK 

Overview

Naoko Takebe is a Hematologist practicing medicine in Oklahoma City, Oklahoma.

Dr. Takebe is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Chondrosarcoma, Alveolar Soft Part Sarcoma, Adult Soft Tissue Sarcoma, and Glioma.

She is actively involved in clinical research, co-authoring 128 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in MD

Hospital Affiliations

O U Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

OU Health Stephenson Cancer Center
800 NE 10th St, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Enrollment Status: Recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Elimusertib, Gemcitabine Hydrochloride, BAY 1895344
Study Phase: Phase 1
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Enrollment Status: Completed
Publish Date: April 29, 2026
Intervention Type: Drug, Other
Study Drugs: Docetaxel, PI3Kbeta Inhibitor AZD8186
Study Phase: Phase 1
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Drugs: Bortezomib, Clofarabine
Study Phase: Phase 1
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drug: Z-Endoxifen
Study Phase: Phase 1
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
Enrollment Status: Withdrawn
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Enrollment Status: Completed
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

128 Total Publications

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.
Journal: JCO precision oncology
Published: June 17, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Thoracic Cancer Clinic

800 NE 10th St # 4500, 
Oklahoma City, OK 
 (0.4 miles away)
405-271-1632
Languages Spoken:
English
See accepted insurances

Raid Aljumaily is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Aljumaily is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances

Sami Ibrahimi is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Ibrahimi is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
45
conditions
Expertise in
45
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Gastrointestinal Cancer Clinic

800 NE 10th St # 4500, 
Oklahoma City, OK 
 (0.4 miles away)
405-271-1632
Languages Spoken:
English
See accepted insurances

Hassan Hatoum is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Hatoum is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Familial Pancreatic Cancer.

Frequently Asked Questions about Dr. Naoko Takebe

How do I make an appointment with Dr. Naoko Takebe?

You can book an appointment with Dr. Naoko Takebe by calling their office at 405-271-1112. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Naoko Takebe a top-rated expert for Chondrosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Naoko Takebe is classified as an Advanced expert for Chondrosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Naoko Takebe specialize in?

While Dr. Naoko Takebe is a Hematology, they have specific expertise in Chondrosarcoma, Alveolar Soft Part Sarcoma, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Naoko Takebe participate in research or clinical trials?

Yes. Dr. Naoko Takebe has published 128 articles and abstracts on conditions like Chondrosarcoma. You can view a list of Dr. Naoko Takebe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Takebe's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile